You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Colorcon
McKesson
Dow
Mallinckrodt
Moodys
Merck

Last Updated: August 7, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR TRAVATAN Z

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

505(b)(2) Clinical Trials for Travatan Z

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Formulation NCT00670033 Travoprost New Formulations in Patients With Open-Angle Glaucoma or Ocular Hypertension Completed Alcon Research Phase 2 2008-04-01 The purpose of this study was to describe the safety and IOP-lowering efficacy of Travoprost New Formulations compared to TRAVATAN® and to vehicle in patients with open-angle glaucoma or ocular hypertension.
New Formulation NCT01452009 Three Month Safety and Efficacy Study of TRAVATAN® Versus Travoprost Ophthalmic Solution, 0.004% Withdrawn Alcon Research Phase 3 2011-11-01 A multi-center, observer-masked, randomized, parallel group efficacy and safety study of TRAVATAN® versus a new formulation of Travoprost Ophthalmic Solution, 0.004%
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Travatan Z

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00047554 Study of TRAVATAN in Subjects With Iris Pigmentation Changes Terminated Alcon Research Phase 4 2003-05-01 The purpose of this study was to monitor iris pigmentation changes over a 5-year period in patients with open-angle glaucoma or ocular hypertension. To be eligible for the study, these individuals must have experienced an iris pigmentation change while previously dosing with TRAVATAN.
NCT00051155 A 6-Week Safety and Efficacy Study of Travatan Compared to Xalcom in Subjects With Open-Angle Glaucoma(OAG) or Ocular Hypertension(OHT) Completed Alcon Research Phase 3 2001-01-01 To compare the safety and IOP-lowering efficacy of TRAVATAN and XALCOM in subjects with open-angle glaucoma or ocular hypertension.
NCT00051168 A Long-term Safety Study of Once-daily Travatan Completed Alcon Research Phase 3 2006-01-01 Long term safety study of TRAVATAN in patients with Open-angle glaucoma or ocular hypertension.
NCT00061503 Mechanism of Action of TRAVATAN 0.004% in Subjects With Glaucoma or Ocular Hypertension Completed Alcon Research Phase 4 2003-04-01 The primary objective of this study is to describe the effect of TRAVATAN 0.004% Ophthalmic Solution on aqueous humor dynamics in subjects with a clinical diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT).
NCT00121147 Additivity Study: Additive Effect on Eye Pressure of Azopt and Alphagan P to Travatan Completed Alcon Research N/A 2003-09-01 The purpose of this study is to compare the additive effect on eye pressure of Azopt and Alphagan P to Travatan.
NCT00121147 Additivity Study: Additive Effect on Eye Pressure of Azopt and Alphagan P to Travatan Completed Hermann Eye Center N/A 2003-09-01 The purpose of this study is to compare the additive effect on eye pressure of Azopt and Alphagan P to Travatan.
NCT00293761 A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension Completed Alcon Research Phase 3 2006-01-01 The purpose of the study is to determine whether a glaucoma therapy is safe and effective in treating patients with open-angle glaucoma or ocular hypertension
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Travatan Z

Condition Name

Condition Name for Travatan Z
Intervention Trials
Ocular Hypertension 38
Open-angle Glaucoma 19
Glaucoma 19
Open Angle Glaucoma 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Travatan Z
Intervention Trials
Glaucoma 46
Ocular Hypertension 40
Hypertension 32
Glaucoma, Open-Angle 31
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Travatan Z

Trials by Country

Trials by Country for Travatan Z
Location Trials
United States 60
Canada 4
Portugal 1
Japan 1
Switzerland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Travatan Z
Location Trials
Texas 9
California 4
Ohio 3
Pennsylvania 3
New York 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Travatan Z

Clinical Trial Phase

Clinical Trial Phase for Travatan Z
Clinical Trial Phase Trials
Phase 4 29
Phase 3 10
Phase 2 7
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Travatan Z
Clinical Trial Phase Trials
Completed 40
Terminated 5
Recruiting 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Travatan Z

Sponsor Name

Sponsor Name for Travatan Z
Sponsor Trials
Alcon Research 37
Allergan 4
Pfizer 3
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Travatan Z
Sponsor Trials
Industry 47
Other 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Merck
McKinsey
Moodys
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.